,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2018-04-05 23:09:00,The first two IPOs of the second quarter are targeting a combined $170 million in the week ahead.,0.07107792049646378,0.005377560388296843,0.9235444664955139,neutral,0.06570035964250565
1,2018-04-05 23:09:00,Subscription billing unicorn Zuora ( ZUO ) and Alzheimer's disease biotech Alzheon ( ALZH ) represent the leading sectors from the first quarter.,0.1695621907711029,0.0065546827390789986,0.8238831162452698,neutral,0.16300751268863678
2,2018-04-05 23:09:00,"Tech deals are up 20% on average year-to-date; while health care deals are up 8%, the sector accounts for both the two best and two worst deals of the year.",0.9221580624580383,0.03476669266819954,0.043075233697891235,positive,0.8873913884162903
3,2018-04-05 23:09:00,"Sign up for a free trial of our premium platform, IPO Pro .",0.3655027151107788,0.010451066307723522,0.624046266078949,neutral,0.3550516366958618
4,2018-04-05 23:09:00,Follow us on Twitter ( @IPOtweet ) and register for our updates on the IPO market.,0.022442135959863663,0.012522934935986996,0.9650349617004395,neutral,0.009919201023876667
5,2018-04-05 23:09:00,"Zuora ( ZUO ), which offers a billing management platform, aims to raise $100 million at a $1.1 billion market value.",0.6762818098068237,0.0096243591979146,0.31409376859664917,positive,0.6666574478149414
6,2018-04-05 23:09:00,"Founded by an early Salesforce.com ( CRM ) executive, the company benefits from an experienced management team, and insiders intend to purchase 12% of the IPO.",0.3988721966743469,0.008785315789282322,0.5923424959182739,neutral,0.3900868892669678
7,2018-04-05 23:09:00,"Zuora has grown subscription revenue at 30%+, and boasts a 110% dollar-based retention rate.",0.9271915555000305,0.01416570320725441,0.058642737567424774,positive,0.9130258560180664
8,2018-04-05 23:09:00,"However, the company spends heavily on sales and marketing, which holds back profitability, and its services segment dragged gross margin down to 52% in 2017.",0.016178004443645477,0.9730442762374878,0.010777810588479042,negative,-0.9568662643432617
9,2018-04-05 23:09:00,"Alzheon ( ALZH ), which is developing small molecule therapies for Alzheimer's disease (AD), is targeting $70 million at a $228 million market value.",0.13077372312545776,0.005216856021434069,0.864009439945221,neutral,0.12555687129497528
10,2018-04-05 23:09:00,"The FDA granted Fast Track designation for the company's sole candidate, ALZ-801, in late 2017, and management expects to begin Phase 3 trial for patients with mild AD later in 2018.",0.5040972232818604,0.010216431692242622,0.48568636178970337,positive,0.4938807785511017
11,2018-04-05 23:09:00,"While Alzheon is addressing a multi-billion dollar market with significant unmet need, ALZ-801 is based on a drug that originally failed in large AD trials and was only revived after retrospective analysis; other drugs addressing beta amyloids, which Alzheon targets, have failed in Phase 3 trials.",0.1524476259946823,0.05790511891245842,0.7896472811698914,neutral,0.0945425033569336
12,2018-04-05 23:09:00,"Eleven companies are eligible to launch IPO roadshows in the upcoming week, headlined by electronic signature platform DocuSign (DOCU), DellEMC spinoff Pivotal Software (PIVI.RC) and spreadsheet-based collaboration platform Smartsheet (SMAR).",0.3702056407928467,0.009954612702131271,0.6198397278785706,neutral,0.3602510392665863
13,2018-04-05 23:09:00,"Others deals that could launch include CIBC spinoff FirstCaribbean International Bank (FCI), HR software provider Ceridian (CDAY), a Michigan commercial bank, a small Chinese fintech and four biotechs.",0.08315430581569672,0.006054231431335211,0.9107914566993713,neutral,0.07710007578134537
14,2018-04-05 23:09:00,11 Deals Could Launch in the Week Ahead Singapore biotech developing cancer therapies using the HER pathway.,0.5438350439071655,0.017753466963768005,0.4384114742279053,positive,0.5260815620422363
15,2018-04-05 23:09:00,"Leading bank in Barbados, the Bahamas and Cayman Islands spun out of CIBC.",0.028269000351428986,0.0709156021475792,0.9008153676986694,neutral,-0.04264660179615021
16,2018-04-05 23:09:00,Licensing antibodies to pharmas and developing its own therapy for lymphoma.,0.14617863297462463,0.005604350473731756,0.8482169508934021,neutral,0.14057427644729614
17,2018-04-05 23:09:00,The Renaissance IPO Indices are market cap weighted baskets of newly public companies.,0.025441057980060577,0.008194190450012684,0.9663646817207336,neutral,0.017246868461370468
18,2018-04-05 23:09:00,The Renaissance IPO Index has returned -0.6% year-to-date and the S&P 500 is down -2.6 % .,0.020146925002336502,0.9601613283157349,0.019691677764058113,negative,-0.9400144219398499
19,2018-04-05 23:09:00,"Renaissance Capital's IPO ETF ( IPO ) tracks the index, and top ETF holdings include Snap (SNAP) and US Foods (USFD).",0.040802933275699615,0.005516197066754103,0.9536808133125305,neutral,0.035286735743284225
20,2018-04-05 23:09:00,"The Renaissance International IPO Index is up 4.9% year-to-date, while the ACWX is down -1.3%.",0.7960916757583618,0.14669913053512573,0.05720919743180275,positive,0.6493925452232361
21,2018-04-05 23:09:00,"Renaissance Capital's International IPO ETF ( IPOS ) tracks the index, and top ETF holdings include Orsted (DONG Energy) and ASR Nederland .",0.05421404168009758,0.005225128028541803,0.9405608177185059,neutral,0.048988912254571915
22,2018-04-05 23:09:00,The article US IPO Week Ahead: Subscription unicorn Zuora kicks off the 2Q IPO market originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.,0.019547002390027046,0.016573607921600342,0.963879406452179,neutral,0.0029733944684267044
23,2018-04-05 23:09:00,Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security.,0.01595228910446167,0.009523943066596985,0.9745237827301025,neutral,0.006428346037864685
24,2018-04-05 23:09:00,"Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.",0.012252476066350937,0.010433714836835861,0.9773138165473938,neutral,0.0018187612295150757
25,2018-04-05 23:09:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
